Exane Derivatives’s Vistra VST Stock Holding History

Exane Derivatives’s Portfolio VST Stock Details VST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,403	Closed	-$79.1K	–	996
2022 Q1	$79.1K	Buy	+3,403	New	+$75.5K	0.02%	503
2020 Q4	–	Sell	-27	Closed	-$503	–	869
2020 Q3	$509	Sell	27 -99,049	-100%	-$1.87M	﹤0.01%	676
2020 Q2	$1.84M	Sell	99,076 -13,968	-12%	-$263K	0.49%	65
2020 Q1	$1.8M	Buy	+113,044	New	+$2.3M	0.5%	50

Other funds holding VST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $77B AUM 10.33% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MMA

Mizuho Markets Americas New York $6.37B AUM 47.14% 1-Year Est. Return

Exane Derivatives's VST Position: Q2 2022 in Review

Exane Derivatives sold out of Vistra (VST) in Q2 2022, closing a stake of 3,403 shares — an estimated $79.1K sold.

Exane Derivatives first reported a position in VST in Q1 2020 and held it in 4 quarters. The position peaked at $1.84M in Q2 2020. 422 funds tracked by Wall St. Rank hold VST as of Q2 2022.

Exane Derivatives reported no remaining Vistra position as of Q2 2022 after selling out during the quarter.
Exane Derivatives sold 3,403 Vistra shares in Q2 2022, an estimated $79.1K.
Exane Derivatives first reported a position in Vistra in Q1 2020 and held it in 4 quarters.
Exane Derivatives's Vistra position peaked at $1.84M in Q2 2020.
422 funds tracked by Wall St. Rank held Vistra as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.